AMA to help docs cash in on EHR stimulus dollars

Share this article:
AMA to help docs cash in on EHR stimulus dollars
AMA to help docs cash in on EHR stimulus dollars

Doctors that demonstrate the "meaningful use" of electronic health records (EHR) in their practices are eligible for at least $44,000 over five years, an incentive the American Medical Association (AMA) is facilitating with a new partnership.

AMA's partnership with UnitedHealth-owned Ingenix will offer physicians a way to "assess and meet their clinical and practice needs," as well as "access information, products and services with a single, secure sign-on," according to an AMA release. The platform is currently in beta testing through a collaboration with the Michigan State Medical Society, and will launch nationwide later this year, according to the release.

The Ingenix CareTracker platform will also help physicians demonstrate meaningful use of an EHR system, the key qualification for payment under the American Reinvestment and Recovery Act, said Bill Miller, EVP, healthcare delivery systems at Ingenix in the release.

A survey conducted by Sermo and AthenaHealth, an EHR provider, found that 80% of responding Sermo docs view EHRs favorably, believing that they improve patient care. However, 90% of the docs surveyed said they agree or strongly agree that EHRs are expensive to purchase, and 60% agree or strongly agree that EHRs "distract from face to face interaction with patients," according to survey results.

"Discussion amongst the Sermo physician community supports the survey's findings of 'holes' in current offerings and more broadly the notion that EHRs have a long way to go towards delivering on the promise of cost savings, freed resources, and better medicine," said Daniel Palestrant, Sermo CEO, in a statement.

Share this article:

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?